argenx Shares Plunge 15% as Vyvgart Trial for Sjögren's Disease Halted

Key Facts

1Shares of argenx SE fell nearly 15% in New York after discontinuing a late-stage trial of its drug Vyvgart.

2The decision involves halting Vyvgart trials for Sjögren's disease, a chronic autoimmune condition affecting tear and saliva glands.

Shares of argenx SE fell nearly 15% in New York after discontinuing a late-stage clinical trial of its drug Vyvgart. Proactive Investors reported that the decision involves halting trials for Sjögren's disease, a chronic autoimmune condition. The move followed a recommendation from an Independent Data Monitoring Committee to stop the Phase 3 UNITY study for futility after an interim analysis found it unable to meet its primary endpoint regarding systemic disease activity.

ARGX closed at $928.44 on October 7, 2026, prior to the announcement that impacted investor confidence in the drug's expanded applications. Analysts at Baird noted that the unexpected timing of the discontinuation likely drove the share price reaction, leading the firm to cut its price target to $823. Despite the Sjögren's trial failure, the company reported that its investigational drug FB102 met primary endpoints in a separate study for celiac disease.